← Back to Search

Behavioral Intervention

iPeer2Peer Mentorship for Teen Heart Failure (iP2P HF Trial)

N/A
Recruiting
Led By Samantha J Anthony, PhD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial tests an online program where young adults mentor younger teens with the same health condition. The goal is to help teens manage their condition better by learning from someone who has been through similar experiences. Mentors and mentees will connect over several months using video calls and text messages.

Who is the study for?
This trial is for teens with heart failure aged 12-17 who are at least 4 months post-diagnosis, and young adults aged 18-25 as mentors. Mentees must commit to regular communication with a mentor over 15 weeks. Mentors need good communication skills, emotional stability, and willingness to train and support mentees. Excluded are those in other peer programs or with significant cognitive impairments or active psychological disorders.
What is being tested?
The iP2P program is being tested to see if it helps teen heart failure patients manage their condition better through online peer mentorship. Participants will be randomly assigned to start the program immediately or after a waiting period (waitlist). They'll use video calls and texts for support over a period of 15 weeks.
What are the potential side effects?
Since this trial involves an educational intervention rather than medication, traditional physical side effects aren't expected. However, participants may experience emotional discomfort due to discussing personal health issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability (Mentees)
Acceptability (Mentors)
Adoption (Mentees)
+5 more
Secondary study objectives
Adherence (Mentees)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: iPeer2Peer ProgramExperimental Treatment1 Intervention
Group II: Standard of Care Waitlist Control GroupActive Control1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for heart failure include ACE inhibitors, which relax blood vessels and reduce the workload on the heart; beta-blockers, which slow the heart rate and decrease blood pressure to improve heart function; diuretics, which help remove excess fluid from the body to reduce swelling and ease breathing; and aldosterone antagonists, which block the effects of aldosterone to prevent fluid retention and further heart damage. These treatments are crucial for heart failure patients as they help manage symptoms, improve quality of life, and reduce hospitalizations. Programs like iPeer2Peer that focus on peer support and disease self-management can enhance adherence to these treatments and empower patients to take an active role in their care.

Find a Location

Who is running the clinical trial?

The Centre Hospitalier Universitaire Sainte-JustineUNKNOWN
British Columbia Children's HospitalOTHER
26 Previous Clinical Trials
15,226 Total Patients Enrolled
The Hospital for Sick ChildrenLead Sponsor
705 Previous Clinical Trials
6,956,879 Total Patients Enrolled
2 Trials studying Heart Failure
122 Patients Enrolled for Heart Failure

Media Library

iPeer2Peer Program (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05709132 — N/A
Heart Failure Research Study Groups: Standard of Care Waitlist Control Group, iPeer2Peer Program
Heart Failure Clinical Trial 2023: iPeer2Peer Program Highlights & Side Effects. Trial Name: NCT05709132 — N/A
iPeer2Peer Program (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05709132 — N/A
~37 spots leftby Apr 2027